# Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

> **NCT06959225** · PHASE3 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 550 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Ruxolitinib Cream
- **DRUG:** Vehicle Cream

## Key facts

- **NCT ID:** NCT06959225
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-23
- **Primary completion:** 2026-10-09
- **Final completion:** 2027-07-11
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06959225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06959225, "Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06959225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*